Trophoblastic thesis of cancer

Federated Search Page Form block

To find clinical trials specific to your diagnosis, talk with your doctor or search online clinical trial databases now. Please note that this link takes you to a separate ASCO website. The next section in this guide is Coping with Treatment. It offers guidance in how to cope with the physical, emotional, social, and financial changes that GTD and its treatment can bring.

Use the menu to choose a different section to read in this guide.

The unitarian or trophoblastic thesis of cancer.

Looking for More About the Latest Research? If you would like additional information about the latest areas of research regarding GTD, explore these related items that take you outside of this guide: To find clinical trials specific to your diagnosis, talk with your doctor or search online clinical trial databases now. Types of Cancer.

Gestational Trophoblastic Disease Guide. Net Guide Gestational Trophoblastic Disease. Medical Illustrations. Risk Factors. Symptoms and Signs. Stage and Risk Grouping. Types of Treatment. About Clinical Trials. Latest Research.

The Unitarian Or Trophoblastic Thesis of Cancer - Ernst T. Krebs - Google книги

Coping with Treatment. Follow-Up Care. Questions to Ask the Health Care Team. The investigators reported a median survival time of 17 months and a mean survival time of At the time the study was reported, two patients were alive: one who had survived 3 years, and one had survived 4 years. The researchers concluded that the 1-year and 2-year survival percentages for this group of patients were superior to those observed for other U. The small number of patients in this study and the absence of a control group are limitations that raise doubts about the reliability of its findings.

It is possible that important, unidentified differences between these patients and other patients diagnosed with stage II to stage IV pancreatic cancer contributed to the relatively long survival. The investigators report that 25 additional patients with pancreatic cancer were seen during the study period but were excluded from study participation.

Eleven of these patients were excluded on the basis of comorbidities, previous treatment, or delay between diagnosis and beginning the program; 14 otherwise eligible patients were excluded on the grounds that they chose not to start the program, complied only briefly, or predicted noncompliance. The second study is a nonrandomized prospective case-control observational study sponsored by the National Center for Complementary and Integrative Health and the National Cancer Institute in which median survival and quality of life were found to be better in patients treated with gemcitabine -based i.

This study was originally planned for randomization but changed after few patients elected to participate in the randomized trial. The same eligibility criteria were used to select patients for both treatment arms. The results of this study were reported in the peer-reviewed Journal of Clinical Oncology.

The enzyme treatment included orally ingested proteolytic enzymes, nutritional supplements , detoxification , and an organic diet as used in the pilot study by Gonzalez and Isaacs. The patients also took specified numbers of capsules with magnesium citrate and Papaya Plus every 4 hours on an empty stomach. The dose for patients with stage II disease was 69 enzyme capsules per day, and the dose for patients with stages III or stage IV was 81 capsules per day.

After day 16, patients had a 5-day rest period and then resumed treatment on day Patients in the experimental arm received proteolytic treatment under the care of a practitioner familiar with the regimen ; those in the chemotherapy arm received treatment by the oncologist they selected. The gemcitabine treatment patients received various gemcitabine-containing regimens, with 19 of the 23 patients receiving a combination of gemcitabine, capecitabine , and docetaxel.

Wikipedia... Might imply foul play regarding B17 trials!

The two groups had similar clinical characteristics. The median survival for the patients in the gemcitabine arm was 14 months and, on the enzyme arm, 4. The paper does not list Dr. Gonzalez as an author, and does not identify him as participating in the study; however, Dr. Gonzalez published comments on his website indicating his participation in the study and detailing his concerns about how the study was conducted, including patient compliance with the prescribed treatment in the enzyme arm.

No data concerning the effectiveness of the Gonzalez regimen for the treatment of cancer patients with other types of cancer have been reported, despite claims that a variety of cancers can be treated. In addition, there is no safety or efficacy information on the regimen in children. No clinical trials of this regimen have been conducted in children, and this extremely difficult regimen may be prohibitive in young children. The developer of the Gonzalez regimen has reported the following adverse effects associated with the regimen : intestinal gas; occasional bloating and indigestion, apparently related to ingestion of porcine pancreatic enzyme ; and flu-like syndromes , allegedly associated with detoxification, including low-grade fever, nonspecific myalgia muscle aches , and nonspecific skin rashes.

There are rare reports of adverse events unrelated to the coffee enemas in patients receiving them. It should be remembered that clinically significant changes in blood chemistries can occur with excessive use of enemas of any kind. Existing clinical data concerning the effectiveness of the Gonzalez regimen as a treatment for cancer are limited and inconclusive. One clinical study , a nonconsecutive case series involving 11 patients with pancreatic cancer , has been reported.

To assist readers in evaluating the results of human studies of integrative, alternative, and complementary therapies for cancer, the strength of the evidence i. To qualify for a level of evidence analysis , a study must:. Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes i.

The resulting two scores are then combined to produce an overall score. For an explanation of the scores and additional information about levels of evidence analysis of CAM treatments for cancer, refer to Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies. The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of Gonzalez Regimen in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. Board members review recently published articles each month to determine whether an article should:. Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

Any comments or questions about the summary content should be submitted to Cancer. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries. Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches.

PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. PDQ Gonzalez Regimen. Permission to use images outside the context of PDQ information must be obtained from the owner s and cannot be granted by the National Cancer Institute.

Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online , a collection of over 2, scientific images. The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.

More information about contacting us or receiving help with the Cancer. Questions can also be submitted to Cancer. Menu Contact Dictionary Search. Understanding Cancer. What Is Cancer? Cancer Statistics. Cancer Disparities. Cancer Causes and Prevention. Risk Factors. Cancer Prevention Overview. Cancer Screening Overview. Screening Tests. Diagnosis and Staging. Questions to Ask about Your Diagnosis.

The unitarian or trophoblastic thesis of cancer

Types of Cancer Treatment. Side Effects of Cancer Treatment. Clinical Trials Information.

Malignant Gestational Trophoblastic Disease - CRASH! Medical Review Series

A to Z List of Cancer Drugs. Questions to Ask about Your Treatment. Feelings and Cancer.

Citation Tools

Adjusting to Cancer. Day-to-Day Life. Support for Caregivers.

trophoblastic thesis of cancer Trophoblastic thesis of cancer
trophoblastic thesis of cancer Trophoblastic thesis of cancer
trophoblastic thesis of cancer Trophoblastic thesis of cancer
trophoblastic thesis of cancer Trophoblastic thesis of cancer
trophoblastic thesis of cancer Trophoblastic thesis of cancer
trophoblastic thesis of cancer Trophoblastic thesis of cancer

Related trophoblastic thesis of cancer

Copyright 2019 - All Right Reserved